Sarepta Therapeutics’ (SRPT) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report published on Saturday morning. Needham & Company LLC currently has a $81.00 price objective on the stock.
Other equities analysts have also issued reports about the company. Oppenheimer Holdings Inc. boosted their price target on Sarepta Therapeutics from $60.00 to $76.00 in a research note on Monday, September 19th. Robert W. Baird restated a buy rating on shares of Sarepta Therapeutics in a report on Friday, June 10th. Janney Montgomery Scott upgraded Sarepta Therapeutics from a neutral rating to a buy rating and boosted their price objective for the company from $30.00 to $65.00 in a report on Monday, September 19th. Piper Jaffray Cos. set a $68.00 price objective on Sarepta Therapeutics and gave the company a buy rating in a report on Tuesday. Finally, Vetr upgraded Sarepta Therapeutics from a sell rating to a hold rating and set a $17.28 price objective for the company in a report on Monday, June 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $58.12.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 57.89 on Friday. The firm’s 50-day moving average price is $40.98 and its 200 day moving average price is $25.39. Sarepta Therapeutics has a one year low of $8.00 and a one year high of $63.73. The firm’s market cap is $2.77 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the business earned ($0.87) earnings per share. Analysts predict that Sarepta Therapeutics will post ($4.23) EPS for the current year.
In other news, CEO Edward M. Md Kaye sold 40,179 shares of the company’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the transaction, the chief executive officer now owns 117,162 shares of the company’s stock, valued at approximately $7,029,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 24,557 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total value of $736,710.00. Following the transaction, the chief executive officer now directly owns 76,983 shares in the company, valued at approximately $2,309,490. The disclosure for this sale can be found here. Insiders own 10.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of SRPT. National Planning Corp boosted its position in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Sarepta Therapeutics by 1.6% in the second quarter. Rhumbline Advisers now owns 46,719 shares of the company’s stock worth $891,000 after buying an additional 721 shares during the period. Teacher Retirement System of Texas boosted its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares during the period. First Allied Advisory Services Inc. boosted its stake in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares during the period. Finally, LGL Partners LLC boosted its stake in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock worth $485,000 after buying an additional 1,000 shares during the period. 65.29% of the stock is currently owned by hedge funds and other institutional investors.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.